Scholars Central

Conference abstractPublished 27 Oct 2014

Biosimilars: Regulatory considerations

Authors: B P Nagori

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Biosimilars also known as follow-on biologics are biologic medical products whose active drug substance(s) are made by a living organism or derived from a living organism using recombinant DNA or controlled gene expression methods. They have been independently developed after the patent protecting the original product has expired. In general, it means that the biological reference medicine must have been authorized for at least 10 years before a similar biological medicine can be made available by another company. Biosimilars are intended to have the same mechanism of action as the original biological medicines and are designed to treat the same diseases as the innovator?s product. Successful development and commercialization of a biosimilar product requires the integration of regulatory strategy, clinical strategy and trial design as well as commercial and market access considerations. Companies looking to develop biosimilars aim to minimize the developmental cost without sacrificing the product quality. They must also address the challenges involved in developing and commercializing biosimilars and identifying the investigators and patients for clinical trials. Regulation of biosimilars is evolving rapidly because of increasing pressure for lower cost versions of biological medicines and continuous improvement in the involved technologies. Recently a number of countries have issued the guidance addressing the regulation of biosimilars and the content of biosimilar applications. WHO also has issued guidelines for regulatory authorities that are seeking to develop standards for biosimilars. This presentation will highlight the present status of regulatory considerations for bio¬similars.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Bioanalysis & Biomedicine.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Bioanalysis & Biomedicine
  • BylineArticles whose byline prints “B P Nagori”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels